Anavex Life Sciences Corp (AVXL)

[bas2020]

To claim that the use of Odds Ratios was "inappropriate" for the AD P2b/3 trial is another false and spun up piece of FUD from you.

The different purposes of a clinical trial and the appropriate use of Odds Ratios is key to appreciate why biotech investors and the market is currently not valuing $AVXL higher.

The "market" isn't in control of the SP; it's collusive manipulation and suppression by your HF handlers... and will end once approvals and/or partnerships are announced by next year.